Toxicity Mechanism of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) as Opportunity for Development of New Targeted Therapies Targeting Aryl Hydrocarbon Receptors (AhR)—Molecular Docking Simulation Study
Future Pharmacology · 17.03.2026 · 6 (1) · 15
DOI: 10.3390/futurepharmacol6010015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 17.03.2026. Verfasst von Andrej Vuckovski und 1 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a highly toxic environmental contaminant whose adverse biological effects are primarily mediated through activation of the aryl hydrocarbon receptor (AhR). Upon ligand binding, AhR undergoes conformational changes that initiate nuclear translocation and transcriptional activation of xenobiotic-responsive genes, contributing to toxicity, carcinogenesis, and dysregulated immune and metabolic responses. Understanding the molecular basis of AhR activation by TCDD is therefore critical for the rational development of targeted therapeutic strategies.
Methods
In this study, molecular docking simulations were employed to characterize the interaction of TCDD and selected AhR antagonists (CH223191, BAY 2416964, GNF-351) with the ligand-binding domain of AhR, with particular emphasis on the canonical PAS-B domain.
Results
Docking analyses identified the PAS-B cavity (pocket C1) as the most biologically relevant binding site for high-affinity ligands, consistent with experimental evidence. Comparative docking of known AhR antagonists revealed stable binding poses characterized by hydrophobic packing, π–π interactions, and hydrogen-bonding networks that competitively block agonist access and prevent receptor activation. These findings support a competitive antagonism mechanism as a viable approach to counteract TCDD-induced AhR signaling.
Conclusions
Collectively, this in silico study provides mechanistic insight into TCDD toxicity at the molecular level and highlights AhR antagonism as a promising strategy for the development of targeted therapies against dioxin-related pathologies.
Zitieren
APA
Vuckovski, A., & Ackova, D. G. (2026). Toxicity Mechanism of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) as Opportunity for Development of New Targeted Therapies Targeting Aryl Hydrocarbon Receptors (AhR)—Molecular Docking Simulation Study. Future Pharmacology, 6(1), 15. https://doi.org/10.3390/futurepharmacol6010015
Vancouver
Vuckovski A, Ackova DG. Toxicity Mechanism of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) as Opportunity for Development of New Targeted Therapies Targeting Aryl Hydrocarbon Receptors (AhR)—Molecular Docking Simulation Study. Future Pharmacology. 2026;6(1):15. doi:10.3390/futurepharmacol6010015
BibTeX
@article{Vuckovski2026,
author = {Vuckovski, Andrej and Ackova, Darinka Gjorgieva},
title = {Toxicity Mechanism of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) as Opportunity for Development of New Targeted Therapies Targeting Aryl Hydrocarbon Receptors (AhR)—Molecular Docking Simulation Study},
journal = {Future Pharmacology},
year = {2026},
volume = {6},
number = {1},
pages = {15},
doi = {10.3390/futurepharmacol6010015}
}
EUVIMED